Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.

@article{VadhanRaj1987EffectsOR,
  title={Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.},
  author={Saroj Vadhan-Raj and Michael J. Keating and Anne LeMaistre and Walter N. Hittelman and K McCredie and Jos{\'e} Mar{\'i}a Guti{\'e}rrez Trujillo and Hal E. Broxmeyer and Catherine Henney and JordanU. Gutterman},
  journal={The New England journal of medicine},
  year={1987},
  volume={317 25},
  pages={
          1545-52
        }
}
The myelodysplastic syndromes are characterized by ineffective hematopoiesis and refractory cytopenias. In an attempt to improve hematopoiesis, we administered recombinant human granulocyte--macrophage colony-stimulating factor (GM-CSF) to eight patients with myelodysplastic syndrome, as part of a Phase I trial. The GM-CSF was given by continuous intravenous infusion daily for two weeks and then again after a two-week rest period. Over the entire dose range tested (30 to 500 micrograms per… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 108 CITATIONS, ESTIMATED 84% COVERAGE

Thrombopoietin: an update on therapeutic potential.

  • BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
  • 1999
VIEW 3 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Granulocyte–macrophage colony-stimulating factor: not just another haematopoietic growth factor

Alejandro Francisco-Cruz, M Aguilar-Santelises, +4 authors Rogelio Hernandez-Pando
  • Medical Oncology
  • 2013
VIEW 1 EXCERPT
CITES BACKGROUND

Revisiting use of growth factors in myelodysplastic syndromes.

  • Asian Pacific journal of cancer prevention : APJCP
  • 2012
VIEW 1 EXCERPT
CITES BACKGROUND

FILTER CITATIONS BY YEAR

1988
2018

CITATION STATISTICS

  • 3 Highly Influenced Citations